Seattle, WA -- (SBWIRE) -- 11/06/2019 -- One of the major advantages of nasal drug delivery system is that the drug circumvents hepatic first-pass metabolism, leading to high bioavailability as compared to drug administered orally. On the contrary, parenteral route of administration is also inconvenient for long term therapeutic treatment.
Nasal drug delivery system is used as substitute to invasive administrations and delivers direct access to systemic circulation. It is a common drug administration method and is preferred for the treatment non-allergic rhinitis, pain, nasal congestion related to sinusitis, acute treatment of migraine, and common cold. Nasal drug delivery is mostly used when there is need for rapid onset of action or to reach the site where other route of administrations are ineffective. It is also used for needle-free vaccination and systematic drug delivery. The liquid nasal preparations can be delivered via droppers, inhalers, spray pumps, nebulizers, or atomizers.
Request Sample Copy of Industry Experts: https://www.coherentmarketinsights.com/insight/request-sample/1944
The global nasal drug delivery systems market size is estimated to be valued at US$ 48.1 billion in 2018 and is expected to witness a CAGR of 6.3% over the forecast period (2018 – 2026).
Nasal cavity is highly vascular, hence it enhances drug absorption, which results in rapid outset of action. Moreover, ease of administration along with non-invasive method is driving adoption of nasal drug delivery systems is drive the global nasal drug delivery systems market growth.
However, typical drawbacks such as histological toxicity or lesser area of absorption as compared to orally administered drug are expected to restrain the global nasal drug delivery systems market growth.
Furthermore, increasing product approvals from regulatory authorities is expected to drive the market growth in the near future. For instance, in 2017, Optinose, an ENT / Allergy specialty pharmaceutical company, received New Drug Application approval for its Xhance, fluticasone propionate, for the indication of nasal polyps in adults. Xhance is a specially designed combination of novel Optinose Exhalation Delivery System and an aqueous suspension of microfine drug delivery for topical intranasal administration via a metered atomizing spray pump. Moreover, the product can be opted for powder and liquid formulation and also addresses the limitation of traditional nasal spray by using its bi-directional delivery.
The PDF for the study can be requested using the following link: https://www.coherentmarketinsights.com/insight/request-pdf/1944
The regional nasal drug delivery systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa by Coherent Market Insights. Among regions, North America nasal drug delivery systems market is estimated to hold dominant position in 2017. This owing to increasing research and development activities by local manufacturers to develop new drug device or delivery system combination.
For instance, Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company, is engaged in applying its Precision Olfactory Delivery (POD) nasal drug delivery platform for drugs such as levodopa powder, insulin liquid, and olanzapine powder for the treatment of Parkinson's disease, Alzheimer's disease and agitation in schizophrenia and bipolar disorder, respectively.
However, Asia Pacific nasal drug delivery systems market is expected to witness rapid growth, owing to increasing prevalence of diseases, which are expected to be treated by intranasal route of drug delivery. For instance, according to Journal of Allergy and Clinical Immunology, 2017, the prevalence of asthma in developed cities of Asia Pacific such as Hong Kong, Japan, and Singapore is as high as 12.4%. Key players are targeting high patient pool in this region for further growth, which is not expected in matured markets such as North America and Europe.
Inquire about Discount on this Report: https://www.coherentmarketinsights.com/insight/request-discount/1944
Major companies operating in the global nasal drug delivery systems market are Merck & Co., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.
Contact Us:
Name: Mr. Raj Shah
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com